Publication | Closed Access
Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species
231
Citations
45
References
2010
Year
ImmunologyGlycobiologyPathologyMgp AssaysPotential Diagnostic ValueMolecular PharmacologyTranslational MedicineRenal FunctionBioanalysisClinical ChemistryChronic Kidney DiseaseProteomicsRenal PharmacologyMineral MetabolismHealth SciencesSodium HomeostasisMedicineVascular PharmacologyMatrix Gla ProteinVascular BiologyRenal PathophysiologyPharmacologyPotassium HomeostasisVitamin K AntagonistsPhysiologyMass SpectrometryDifferent AssaysNephrology
Matrix γ‑carboxyglutamate protein (MGP) inhibits vascular calcification and exists in circulating species that differ by incomplete vitamin K‑dependent carboxylation and serine phosphorylation. The study quantified MGP in healthy controls, rheumatic disease, aortic valve disease, end‑stage renal disease patients, and volunteers before and after vitamin K supplementation or antagonism using two commercial competitive and two novel sandwich assays. Assay comparisons revealed substantial differences in disease and vitamin K response, with the dp‑ucMGP sandwich assay being most sensitive, demonstrating that distinct MGP species assays can evaluate specific aspects of the MGP system.
Matrix γ-carboxyglutamate (Gla) protein (MGP) is an important local inhibitor of vascular calcification, which can undergo two post-translational modifications: vitamin K-dependent γ-glutamate carboxylation and serine phosphorylation. While carboxylation is thought to have effects upon binding of calcium-ions, phosphorylation is supposed to affect the cellular release of MGP. Since both modifications can be exerted incompletely, various MGP species can be detected in the circulation. MGP levels were measured with two commercially available competitive and two novel sandwich assays in healthy controls, in patients with rheumatic disease, aortic valve disease, and end-stage renal disease, as well as in volunteers after vitamin K supplementation (VKS) and treatment with vitamin K antagonists (VKA). Major differences were found between the MGP assays, including significantly different behaviour with regard to vascular disease and the response to VKA and VKS. The dual-antibody assay measuring non-phosphorylated, non-carboxylated MGP (dp-ucMGP) was particularly sensitive for these changes and would be suited to assess the vascular vitamin K status. We conclude that the different assays for particular circulating MGP species allows the assessment of various aspects of the MGP system.
| Year | Citations | |
|---|---|---|
Page 1
Page 1